Barclays
LXEO icon

Barclays’s Lexeo Therapeutics LXEO Stock Holding History

Barclays’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$92.9K Buy
27,482
+11,225
+69% +$50.8K ﹤0.01% 4337
2026
Q2 		$75.7K Buy
16,257
+4,092
+34% +$22.1K ﹤0.01% 4167
2026
Q1 		$69.8K Sell
12,165
-176,589
-94% -$1.25M ﹤0.01% 4179
2025
Q4 		$1.87M Buy
188,754
+77,175
+69% +$704K ﹤0.01% 2981
2025
Q3 		$741K Sell
111,579
-4,563
-4% -$22.1K ﹤0.01% 3553
2025
Q2 		$467K Buy
116,142
+69,475
+149% +$228K ﹤0.01% 3792
2025
Q1 		$162K Sell
46,667
-8,494
-15% -$37.6K ﹤0.01% 4159
2024
Q4 		$363K Buy
55,161
+4,951
+10% +$39K ﹤0.01% 4017
2024
Q3 		$454K Buy
50,210
+31,057
+162% +$370K ﹤0.01% 3842
2024
Q2 		$307K Sell
19,153
-3,776
-16% -$54.8K ﹤0.01% 3333
2024
Q1 		$360K Buy
22,929
+7,412
+48% +$116K ﹤0.01% 3788
2023
Q4 		$208K Buy
+15,517
New +$193K ﹤0.01% 4401

Other funds holding LXEO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Barclays's LXEO Position: Q3 2026 in Review

Barclays increased its Lexeo Therapeutics (LXEO) stake by 69% in Q3 2026, buying an estimated $50.8K and bringing the position to 27,482 shares worth $92.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4337.

Barclays first reported a position in LXEO in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.87M in Q4 2025. 60 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

  • Barclays held 27,482 shares of Lexeo Therapeutics worth $92.9K as of Q3 2026.
  • Barclays bought 11,225 Lexeo Therapeutics shares in Q3 2026, an estimated $50.8K.
  • Lexeo Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4337 holding.
  • Barclays first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • Barclays's Lexeo Therapeutics position peaked at $1.87M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.